FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic ...
FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced that the FDA has approved Rasuvo (methotrexate) subcutaneous auto-injector for the management of rheumatoid arthritis, polyarticular ...
The US Food and Drug Administration (FDA) has approved a subcutaneous injectable methotrexate delivered in an auto-injector (Rasuvo, Medac Pharma) for rheumatoid arthritis (RA), polyarticular-course ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback